JP2021514365A5 - - Google Patents

Info

Publication number
JP2021514365A5
JP2021514365A5 JP2020543919A JP2020543919A JP2021514365A5 JP 2021514365 A5 JP2021514365 A5 JP 2021514365A5 JP 2020543919 A JP2020543919 A JP 2020543919A JP 2020543919 A JP2020543919 A JP 2020543919A JP 2021514365 A5 JP2021514365 A5 JP 2021514365A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
activity inhibitor
ire1α
endoribonuclease activity
Prior art date
Application number
JP2020543919A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019158689A5 (https=
JP2021514365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/053807 external-priority patent/WO2019158689A1/en
Publication of JP2021514365A publication Critical patent/JP2021514365A/ja
Publication of JPWO2019158689A5 publication Critical patent/JPWO2019158689A5/ja
Publication of JP2021514365A5 publication Critical patent/JP2021514365A5/ja
Pending legal-status Critical Current

Links

JP2020543919A 2018-02-16 2019-02-15 肝疾患を処置するための方法及び組成物 Pending JP2021514365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305169.7 2018-02-16
EP18305169 2018-02-16
PCT/EP2019/053807 WO2019158689A1 (en) 2018-02-16 2019-02-15 Methods and compositions for treating liver diseases

Publications (3)

Publication Number Publication Date
JP2021514365A JP2021514365A (ja) 2021-06-10
JPWO2019158689A5 JPWO2019158689A5 (https=) 2022-02-18
JP2021514365A5 true JP2021514365A5 (https=) 2022-02-18

Family

ID=61283136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543919A Pending JP2021514365A (ja) 2018-02-16 2019-02-15 肝疾患を処置するための方法及び組成物

Country Status (4)

Country Link
US (2) US20210085643A1 (https=)
EP (1) EP3752135A1 (https=)
JP (1) JP2021514365A (https=)
WO (1) WO2019158689A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355356A4 (en) * 2021-06-15 2025-05-14 Yale University Compounds and methods for treating or preventing autosomal dominant polycystic kidney disease (ADPKD), autosomal dominant polycystic liver disease (ADPLD), and/or autosomal recessive polycystic kidney disease
CN113647359A (zh) * 2021-08-15 2021-11-16 芜湖职业技术学院 注射衣霉素诱导急性肝损伤小鼠模型的构建方法
KR102718502B1 (ko) * 2021-10-13 2024-10-16 단국대학교 천안캠퍼스 산학협력단 쌍별귀뚜라미 가수분해물을 유효성분으로 함유하는 비알코올성 지방간 질환 예방 또는 개선용 식품 조성물 및 이의 제조방법
CN114712514B (zh) * 2022-03-03 2023-03-31 浙江大学 用于局部和全身性减脂的纳米制剂及其应用
CN116549442A (zh) * 2023-06-08 2023-08-08 复旦大学 Stf-083010在制备防治主动脉夹层药物中的应用
CN119185312B (zh) * 2024-10-11 2026-04-21 浙江大学 盐酸胺苯吖啶在制备防治纤维化疾病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2555768B1 (en) * 2010-04-05 2018-08-29 Fosun Orinove Pharmatech, Inc. Ire-1 inhibitors
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2020019107A1 (en) * 2018-07-23 2020-01-30 Fosun Orinove Pharmatech, Inc. IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT

Similar Documents

Publication Publication Date Title
JP2021514365A5 (https=)
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
SA521422068B1 (ar) عوامل مساعدة لـ glp-1r واستخداماتها
JP2007051159A5 (https=)
JP2021530451A5 (https=)
JP2016512425A5 (https=)
PE20212108A1 (es) Compuestos dirigidos a brm y metodos de uso asociados
NO20083793L (no) Antistoffer mot amyloid-beta peptid
PE20140963A1 (es) Compuestos de isoindolina para el tratamiento de cancer
RU2018106914A (ru) 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция
CN113412260A (zh) 己酮糖激酶抑制剂及其用途
CN110036014A (zh) 一种具有axl抑制活性的化合物及其制备和应用
JP2024028337A5 (https=)
BRPI0413490A (pt) novos compostos
JP2019059781A5 (https=)
CR9721A (es) Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
JP2017113019A5 (https=)
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
JP2008526765A5 (https=)
JPWO2020006264A5 (https=)
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
JP2018503685A5 (https=)
JP2021535175A5 (https=)
TN2009000144A1 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement du cancer